Perampanel: Newly Approved Novel Antiepileptic Medication for Partial-Onset Seizures
Evaluation of: French JA, Krauss GL, Steinhoff BJ et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global Phase III study 305. Epilepsia doi:10.1111/j.1528- 1167.2012.03638.x (2012) (Epub ahead of print). Epilepsy is characterized by two or more unprovoked seizures. The number of individuals burdened by recurrent seizures in the USA alone is approximated at around 2 million, with the vast majority of patients maintained on chronic medical management for appropriate seizure control. Perampanel is an oral, noncompetitive antagonist of Î±-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptor that has been approved by the European Medicines Agency and the US FDA under the trade name Fycompa® (Eisai Medical Research Laboratories, Hatfield, UK) as an adjunct treatment of partial-onset seizures in patients aged ‰¥12 years. The article under review is a Phase III randomized, placebo-controlled, double-blind study that demonstrates the efficacy and safety of an 8- and 12Ã¢‚¬'mg daily oral dose of perampanel with greater mean percentage seizure frequency reduction at 8-mg daily dose. The study is discussed in relation to the current understanding of cellular mechanisms of neuronal excitability leading to epileptogenicity, as well as clinical application of novel and established antiepileptic agents.
Medical Subject Headings
Expert Review of Neurotherapeutics
Digital Object Identifier (DOI)
Shvarts, Vladimir and Chung, Steve, "Perampanel: Newly Approved Novel Antiepileptic Medication for Partial-Onset Seizures" (2013). Neurology. 252.